Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06106256 · ClinicalTrials.gov registry record · NA
Three-Axis Wearable Adaptive Vestibular Stimulator
A NA study of Motion Sickness, sponsored by Mayo Clinic.
- Active
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06106256: Active NA study of Motion Sickness, sponsored by Mayo Clinic.
NCT06106256 is a NA study of Motion Sickness that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 40 participants, below the 149-participant average among 6 other Motion Sickness trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06106256, a NA study of Motion Sickness, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to improve current galvanic vestibular stimulation (GVS) technology to ease the motion sickness often associated with virtual reality (VR) simulation.
Primary Outcome
This index allowed a comparison of motion sickness severity across subjects that may each present with a different constellation of symptoms like nausea, skin color, sweating, salivation, drowsiness, headache, and dizziness. The approach is to have the subject and/or observer grade the subjective intensity of different modalities of symptoms and signs (described below) as slight, moderate or severe. Overall motion sickness severity is then derived from a sum of scores resulting in a weighted "ma
Conditions Studied
Interventions
- DEVICE Galvanic Vestibular Stimulation (GVS)
- OTHER Flight simulations in virtual reality (VR)
- OTHER 3-DOF Bertec Portable Essential's dual-balance force plate system
Study Locations (1)
Arizona
- Mayo Clinic Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-11-15 |
| Est. Completion | 2026-12 |
| Phase | NA |
What the registry record for NCT06106256 still lists
NCT06106256 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 149-participant average among 6 other Motion Sickness trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Motion Sickness appearing as the primary indexed condition, and to 3 interventions - of which Galvanic Vestibular Stimulation (GVS) is the first listed.
NCT06106256 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT06106256 about?
NCT06106256 is a clinical study titled "Three-Axis Wearable Adaptive Vestibular Stimulator". The purpose of this study is to improve current galvanic vestibular stimulation (GVS) technology to ease the motion sickness often associated with virtual reality (VR) simulation.
What is the current status of trial NCT06106256?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2023-11-15. Estimated completion is 2026-12.
What conditions does trial NCT06106256 study?
This clinical trial studies the following conditions: Motion Sickness.
What interventions are being tested in trial NCT06106256?
The interventions under investigation include: Galvanic Vestibular Stimulation (GVS) (DEVICE), Flight simulations in virtual reality (VR) (OTHER), 3-DOF Bertec Portable Essential's dual-balance force plate system (OTHER).
Who is sponsoring clinical trial NCT06106256?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06106256 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Motion Sickness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
StableEyes With Active Neurofeedback
RECRUITING · NA
-
Evaluation of a Device to Reduce Motion Sickness and Spatial Disorientation
RECRUITING · NA
-
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
RECRUITING · Phase 2
-
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
ACTIVE NOT RECRUITING · Phase 3
-
Vestibulo-Ocular Reflex Function in Individuals With Chronic Motion Sensitivity Cross-Sectional Study
COMPLETED
-
Nebulizer Delivery of Intranasal Scopolamine
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI